In fact, in vivo NK depletion was shown to abrogate the anti-tumor properties of sFKN, and CD4 and CD8 T-cell depletion also contributed to therapeutic efficacy in a mouse model of lung cancer, although these results were obtained in combination with anti-PD-1 immunotherapy [67] (Figure 3c). The gene discussed is CD8A; the disease is neoplasm.